Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications
Abstract Background Fingolimod, an immunomodulatory agent, is used for the treatment of relapsing–remitting multiple sclerosis (RRMS). Fingolimod-associated macular edema (FAME) is a known complication with an incidence of 0.4%. The current recommendation for treatment of FAME is cessation of fingol...
Main Authors: | Rachel Husmann, John B. Davies, Malik Ghannam, Brent Berry, Praful Kelkar |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-03-01
|
Series: | Clinical and Molecular Allergy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12948-020-00119-4 |
Similar Items
-
Fingolimod Associated Bilateral Cystoid Macular Edema—Wait and See?
by: Refik Pul, et al.
Published: (2016-12-01) -
Acute onset of fingolimod-associated macular edema
by: Mohamed Kamel Soliman, et al.
Published: (2016-12-01) -
Incidence of uveitis and macular edema among patients taking fingolimod 0.5 mg for multiple sclerosis
by: Scott Joseph Sonne, et al.
Published: (2020-09-01) -
Factors predicting response of pseudophakic cystoid macular edema to topical steroids and nepafenac
by: Sabyasachi Sengupta, et al.
Published: (2018-01-01) -
Topical nepafenac in the treatment of center involving diabetic macular edema
by: T P Vignesh
Published: (2019-01-01)